These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 34392078)

  • 21. Association between covid-19 vaccination, SARS-CoV-2 infection, and risk of immune mediated neurological events: population based cohort and self-controlled case series analysis.
    Li X; Raventós B; Roel E; Pistillo A; Martinez-Hernandez E; Delmestri A; Reyes C; Strauss V; Prieto-Alhambra D; Burn E; Duarte-Salles T
    BMJ; 2022 Mar; 376():e068373. PubMed ID: 35296468
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety and immunogenicity of intradermal administration of fractional dose CoronaVac
    Chatsiricharoenkul S; Niyomnaitham S; Posen HJ; Toh ZQ; Licciardi PV; Wongprompitak P; Duangchinda T; Pakchotanon P; Chantima W; Chokephaibulkit K
    Front Immunol; 2022; 13():1010835. PubMed ID: 36268028
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Acute Transverse Myelitis after COVID-19 Vaccination.
    Hsiao YT; Tsai MJ; Chen YH; Hsu CF
    Medicina (Kaunas); 2021 Sep; 57(10):. PubMed ID: 34684047
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Age-Stratified Risk of Cerebral Venous Sinus Thrombosis After SARS-CoV-2 Vaccination.
    Krzywicka K; van de Munckhof A; Sánchez van Kammen M; Heldner MR; Jood K; Lindgren E; Tatlisumak T; Putaala J; Kremer Hovinga JA; Middeldorp S; Levi MM; Cordonnier C; Arnold M; Zwinderman AH; Ferro JM; Coutinho JM; Aguiar de Sousa D
    Neurology; 2022 Feb; 98(7):e759-e768. PubMed ID: 34921101
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An Argentinean cohort of patients with rheumatic and immune-mediated diseases vaccinated for SARS-CoV-2: the SAR-CoVAC Registry-protocol and preliminary data.
    Isnardi CA; Schneeberger EE; Kreimer JL; Luna PC; Echeverría C; Roberts K; de la Vega MC; Virasoro BM; Landi M; Quintana R; Exeni MED; Kogan N; Petkovic I; Pereira D; De Los Ángeles Correa M; Zelaya MD; Tissera Y; Elkin MSG; Pisoni CN; Alonso C; Cogo AK; Cosatti MA; García L; Retamozo C; de Los Ángeles Severina M; Nieto RE; Rosemffet M; Mussano E; Bertoli A; Savio VG; Cosentino V; Pons-Estel GJ
    Clin Rheumatol; 2022 Oct; 41(10):3199-3209. PubMed ID: 35760939
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Reactogenicity among health care workers following a BNT162b2 or mRNA-1273 second dose after priming with a ChAdOx1 nCOV-19 vaccine.
    Baldolli A; Fournier A; Verdon R; Michon J
    Clin Microbiol Infect; 2022 Jun; 28(6):885.e1-885.e5. PubMed ID: 35182759
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Case of Heart Transplantation for Fulminant Myocarditis After ChAdOx1 nCoV-19 Vaccination.
    Kim SH; Lee SY; Kim GY; Oh JS; Kim J; Chun KJ; Ju MH; Lee CH; Song YJ; Na JY
    J Korean Med Sci; 2022 Apr; 37(13):e104. PubMed ID: 35380028
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of Inactivated SARS-CoV-2 Vaccines and ChAdOx1 nCoV-19 Vaccination to Prevent COVID-19 in Thai Households (VacPrevent trial).
    Muadchimkaew M; Siripongboonsitti T; Wongpatcharawarakul S; Boonsankaew C; Tawinprai K; Soonklang K; Mahanonda N
    Int J Infect Dis; 2022 Nov; 124():190-198. PubMed ID: 36180032
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Humoral response to SARS-CoV-2 adenovirus vector vaccination (ChAdOx1 nCoV-19 [AZD1222]) in heart transplant recipients aged 18 to 70 years of age.
    Tanner R; Starr N; Chan G; Dempsey E; Heffernan E; Newman E; O'Neill J; Hannan MM; Lynch B; Joyce E
    J Heart Lung Transplant; 2022 Apr; 41(4):492-500. PubMed ID: 35090809
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Herpes zoster following vaccination with ChAdOx1 nCoV-19 Coronavirus vaccine (recombinant).
    Job AM; Sudhamani B; Mohan M; Mohanasundaram SN
    Indian J Public Health; 2022; 66(1):83-85. PubMed ID: 35381724
    [TBL] [Abstract][Full Text] [Related]  

  • 31. COVID-19 vaccine type-dependent differences in immunogenicity and inflammatory response: BNT162b2 and ChAdOx1 nCoV-19.
    Heo JY; Seo YB; Kim EJ; Lee J; Kim YR; Yoon JG; Noh JY; Cheong HJ; Kim WJ; Yoon SY; Choi JY; Lee YJ; Lee HW; Kim SS; Kim B; Song JY
    Front Immunol; 2022; 13():975363. PubMed ID: 36119092
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effectiveness of rAd26-rAd5, ChAdOx1 nCoV-19, and BBIBP-CorV vaccines for risk of infection with SARS-CoV-2 and death due to COVID-19 in people older than 60 years in Argentina: a test-negative, case-control, and retrospective longitudinal study.
    Rearte A; Castelli JM; Rearte R; Fuentes N; Pennini V; Pesce M; Barbeira PB; Iummato LE; Laurora M; Bartolomeu ML; Galligani G; Del Valle Juarez M; Giovacchini CM; Santoro A; Esperatti M; Tarragona S; Vizzotti C
    Lancet; 2022 Mar; 399(10331):1254-1264. PubMed ID: 35303473
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunogenicity evaluation of ChAdox1 nCov-19 (AZD1222) vaccine in solid cancer patients in Chulabhorn Hospital.
    Limpawittayakul P; Sungkasubun P; Chaiwiriyawong W; Supavavej A; Weerasubpong B; Siripaibun J; Phanthunane C; Lamlertthon W; Ungtrakul T; Tawinprai K; Tantiyavarong W; Samdaengpan C
    Hum Vaccin Immunother; 2022 Nov; 18(6):2104058. PubMed ID: 35976687
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hypothesis: Possible influence of antivector immunity and SARS-CoV-2 variants on efficacy of ChAdOx1 nCoV-19 vaccine.
    Zamai L; Rocchi MBL
    Br J Pharmacol; 2022 Jan; 179(2):218-226. PubMed ID: 34331459
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparative analysis of ChAdOx1 nCoV-19 and Ad26.COV2.S SARS-CoV-2 vector vaccines.
    Michalik S; Siegerist F; Palankar R; Franzke K; Schindler M; Reder A; Seifert U; Cammann C; Wesche J; Steil L; Hentschker C; Gesell-Salazar M; Reisinger E; Beer M; Endlich N; Greinacher A; Völker U
    Haematologica; 2022 Apr; 107(4):947-957. PubMed ID: 35045692
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Postvaccinal Encephalitis after ChAdOx1 nCov-19.
    Zuhorn F; Graf T; Klingebiel R; Schäbitz WR; Rogalewski A
    Ann Neurol; 2021 Sep; 90(3):506-511. PubMed ID: 34324214
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data.
    Shaw RH; Stuart A; Greenland M; Liu X; Nguyen Van-Tam JS; Snape MD;
    Lancet; 2021 May; 397(10289):2043-2046. PubMed ID: 33991480
    [No Abstract]   [Full Text] [Related]  

  • 38. Bilateral Panuveitis Mimicking Vogt-Koyanagi-Harada Disease following the First Dose of ChAdOx1 nCoV-19 Vaccine.
    Kim SY; Kang MS; Kwon HJ
    Ocul Immunol Inflamm; 2022 Jul; 30(5):1218-1221. PubMed ID: 35113750
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Herpes simplex encephalitis following ChAdOx1 nCoV-19 vaccination: a case report and review of the literature.
    Moslemi M; Ardalan M; Haramshahi M; Mirzaei H; Sani SK; Dastgir R; Dastgir N
    BMC Infect Dis; 2022 Mar; 22(1):217. PubMed ID: 35241013
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fertility rates and birth outcomes after ChAdOx1 nCoV-19 (AZD1222) vaccination.
    Hillson K; Clemens SC; Madhi SA; Voysey M; Pollard AJ; Minassian AM;
    Lancet; 2021 Nov; 398(10312):1683-1684. PubMed ID: 34688353
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.